AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03483688 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-directed CAR-T cells
Description: CD19-directed CAR-T cells single infusion intravenously at a target dose of 0.5-5.0 x 10\^6 anti-CD19 CAR+ T cells/kg
Study NCT03747016 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high-energy digestible food E2
Description: The women undergoing Cesarean section are given high energy digestible food 300ml before surgery
Study NCT03747016 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: glucose injection G2
Description: The women undergoing Cesarean section are given glucose injection 300ml before surgery
Study NCT03747016 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: normal saline N2
Description: The women undergoing Cesarean section are given normal saline 300ml before surgery
Study NCT03747016 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high-energy digestible food E1
Description: The women in delivery room are given high energy digestible food 300ml.
Study NCT03747016 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: glucose injection G1
Description: The women in delivery room are given glucose injection 300ml.
Study NCT03747016 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: normal saline N1
Description: The women in delivery room are given normal saline 300ml.
Study NCT02823262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast Cancer Treatment Decision Aid for women 70+
Description: We developed a decision aid on breast cancer treatment for women 70 years or older newly diagnosed with estrogen receptor positive (ER+), clinically lymph node negative (LN-), HER2 negative (HER2-), breast cancers that are 3 centimeters or less. The DA was written using low literacy principles and provides information on the benefits and risks of mastectomy vs. breast conserving surgery (BCS), radiotherapy after BCS, and of hormonal therapies (e.g., anastrozole). It also considers the impact of competing health issues on older women's treatment choices.
Study NCT02823262 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study NCT01109901 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: anterior subcutaneous transposition
Description: transposition of ulnar nerve into subcutaneous bed
Study NCT01109901 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anterior submuscular transposition
Description: transposition of ulnar nerve into muscular tissue
Study NCT01414088 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isotonic saline 0,9 mg/ml
Description: infusion, 23 ml/kg, during 50 minutes
Study NCT01414088 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypertonic saline 2,9 mg/ml
Description: infusion, 7 ml/kg, during 50 minutes
Study NCT01414088 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: glucose 5%
Description: infusion, 23 ml/kg, during 50 minutes
Study NCT03005847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fermented papaya preparation
Description: dietary supplementation with fermented papaya preparation
Study NCT04215354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic field
Description: Low pulsed electromagnetic field induced by BEMER machine model type: B.BOX Professional, model NO: 420200, 12-15 Volt, with maximum 300 Watt and average flux density around 35 microtesla- (BEMER Liechtenstein product, USA). Mattress which is flexible, 6 flat coil was used for whole body therapy.
Study NCT04215354 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic field
Description: Low pulsed electromagnetic field induced by BEMER machine model type: B.BOX Professional, model NO: 420200, 12-15 Volt, with maximum 300 Watt and average flux density around 35 microtesla- (BEMER Liechtenstein product, USA). Mattress which is flexible, 6 flat coil was used for whole body therapy.
Study NCT04215354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Wii Fit plus machine which required balance board . It is a video game console designed by Nintendo 2009
Study NCT01180140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seamguard
Description: GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement is specifically engineered to reduce the incidence of perioperative leaks and bleeding in a variety of open and minimally invasive surgeries. Then, after six months, it is completely absorbed eliminating the risk of a prolonged inflammatory response.
Study NCT03430882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT03430882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT03430882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO
Study NCT00084422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lestaurtinib
Description: Given orally twice daily x 5 consecutive days followed by a two day rest. 28 days = 1 treatment course. Courses repeated indefinitely without gap provided patient has recovered course from toxicities and no DLTs. Dose level assigned according to the planned dose escalation schedule.
Study NCT03120390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo usual care
Study NCT03120390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo AE
Study NCT03120390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo RE
Study NCT03120390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03120390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03120390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Device
Description: Receive Polar heart rate monitor
Study NCT03120390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03120390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03120390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03120390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02717871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PACK-CXL
Description: Local anesthesia~- Oxybuprocaine or Tetracaine, 1 drop each, applied together, every 3 minutes, total of 3 times~Abrasio - Abrasio: 1 mm around the borders of the infiltrate/ulcer~Corneal scrape~Hypo-osmolaric riboflavin solution~- Apply one drop every 2 minutes for 20 minutes~UV-A irradiation~* 3 mW/cm2 for 30 minutes or 9 mW/cm2 for 10 minutes, 18 mW/cm2 for 5 minutes, 30 mW/cm2 for 3 minutes all allowed (see paper Richoz et al)~* Treatment diameter: use a irradiation diameter of 6 to 8 mm, keep the infiltrate/ulcus centered.~Additional postoperative treatment~* Homatropin or Scopolamin, if anterior chamber reaction~* Systemic NSAID/NSAR, if substantial pain~* Do not use: topical or systemic steroids, topical NSAID/NSAR, paracetamol, vitamin A ointment, patching
Study NCT02717871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin in combination with either tobramycin or gentamicin
Description: Control arm consists of standard topical antimicrobial therapy recommended for the treatment of microbial keratitis by the American Academy of Ophthalmology.~Initial empiric topical antibiotic therapy (eye drops or ocular ointment):~1a. Cefazolin (50mg/ml) in combination with either tobramycin (9-14mg/ml) or gentamicin (9-14mg/ml).
Study NCT02717871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cycloplegic agents (cyclopentolate 1% eye drops)
Description: Cycloplegic agents (cyclopentolate 1% eye drops): to decrease pain and synechia risk is at the physician discretion.
Study NCT02717871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroquinolones (Besifloxacin ; ciprofloxacin ; gatifloxacin ; levofloxacin ; moxifloxacin ; ofloxacin )
Description: Fluoroquinolones (Besifloxacin 6 mg/ml; ciprofloxacin 3 mg/ml; gatifloxacin 3 mg/ml; levofloxacin 15 mg/ml; moxifloxacin 5 mg/ml; ofloxacin 3 mg/ml)
Study NCT03244592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Matched placebo
Study NCT02717871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids (prednisolone acetate 0.5% or 1% eye drops)
Description: Corticosteroids (prednisolone acetate 0.5% or 1% eye drops): use of corticosteroids for patients included in the study only after complete closure of the epithelium
Study NCT01511627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General Anesthesia + Spinal anesthesia combined
Description: All patients will receive a preoperative multimodal analgesic regime:~* Tylenol® 975mg per os~* Naproxen® 500 mg per os~Patients will receive a spinal anesthetic with:~* Bupivacaine 0.5% 10 mg~* Fentanyl 10ug~* Epidural Morphine 150ug~After the spinal, a general anesthetic will be induced using:~* Midazolam 1 - 2 mg intravenously~* Fentanyl 1 - 2 ug/kg intravenously~* Propofol 1-3 mg/kg intravenously~* Rocuronium 0.3 - 0.9mg/kg intravenously~* followed by endotracheal intubation. Maintenance of anesthesia with sevoflurane, oxygen and air.~* Intraoperative Morphine 0 - 0.3mg/kg or Fentanyl 0 - 7.5ug/kg to maintain MAP and heart rate within 20% of baseline.~* Phenylephrine and Ephedrine can be used to support blood pressure and heart rate within 20% of baseline.~* Dexamethasone 4mg and Ondansetron 4mg intravenously~* Neostigmine 3mg and Glycopyrrolate 0.6mg intravenously Patients will receive a Morphine PCA to be initiated in the Post Anesthetic Care Unit (PACU).
Study NCT01511627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia (control group)
Description: All patients will receive a preoperative multimodal analgesic regime:~* Tylenol® 975mg per os~* Naproxen® 500 mg per os~Group I (General anesthetic) patients will receive a general anesthetic :~* Midazolam 1 - 2 mg intravenously~* Fentanyl 1 - 2 ug/kg intravenously~* Propofol 1-3 mg/kg intravenously~* Rocuronium 0.3 - 0.9mg/kg intravenously~* followed by endotracheal intubation. Maintenance of anesthesia with sevoflurane, oxygen and air.~* Intraoperative Morphine 0 - 0.3mg/kg or Fentanyl 0 - 7.5ug/kg. to maintain MAP and heart rate within 20% of baseline.~* Phenylephrine and Ephedrine can be used to support blood pressure and heart rate within 20% of baseline.~* Dexamethasone 4mg and Ondansetron 4mg intravenously~* Neostigmine 3mg and Glycopyrrolate 0.6mg intravenously~Patients will receive a Morphine PCA as per protocol that will be initiated in the Post Anesthetic Care Unit (PACU).
Study NCT01866475 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EZ-IO
Description: To have an EZ-IO placed up to 48 hours
Study NCT03957096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD47M
Description: SGN-CD47M administered intravenously
Study NCT00668395 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Efavirenz
Description: The metabolism and pharmacokinetics of efavirenz were assessed at a single 600 mg oral dose of efavirenz and after subjects took multiple doses of efavirenz (600 mg/day orally for 17 days).
Study NCT02285049 — intervention group
Intervention type: OTHER
Intervention: Urticaria Control Test
Description: * The patients get the 1st UAS28 form and four-week appointment to follow up.~* Collect completed UAS28 assessment, Patient's global assessment of disease severity (PatGA-LS) and Physician's global assessment of disease control (PhyGA-LS)~* Then patients fill the 1st UCT and DLQI questionnaire by themselves.~* The patients get the 2nd UAS28 form and four-week appointment to follow up.~* At the 2nd visit, collect completed UAS28 assessment. Assessment the severity of chronic urticaria symptoms by Patient's global assessment of disease severity (PatGA-LS) and Physician's global assessment of disease control (PhyGA-LS). The patients fill the UCT and DLQI and questionnaire by themselves.
Study NCT04459754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuzheng Yiliu Formulation
Description: The prescription for colorectal cancer Fuzheng Yiliu formulation is a combination of 13 herbal components and it is available in granules form to be dissolved in hot water for consumption.
Study NCT03114995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Study NCT02522520 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer intervention
Description: 12 weeks physical activity intervention (supervised/non-supervised)
Study NCT02522520 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer + hospital based intervention
Description: 12 weeks physical activity intervention (supervised/non-supervised)
Study NCT02522520 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omron Walking Style pro. 20
Study NCT01755286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-201
Description: Single intra-operative injection
Study NCT01755286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intratympanic injection
Study NCT01755286 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Simulated single intratympanic injection
Study NCT02182882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GINSANA
Study NCT02182882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01039090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous Apomorphine infusion
Description: Continuous Apomorphine infusion during 6 months
Study NCT01039090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual dopaminergic per os treatment
Description: No specific change in the dopaminergic per os treatment
Study NCT04896905 — intervention group
Intervention type: OTHER
Intervention: Rehabilitation
Description: Rehabilitative procedures in isolation ward
Study NCT03040219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: Tablets
Study NCT03040219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Tablets
Study NCT01697761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment Group
Description: patients receive herbs-partitioned moxibustion for 2 cones and acupuncture for 30 minutes，3 times a week for 12 weeks
Study NCT01697761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: patients receive shallow needing and bran-partitioned moxibustion with the stimulation same to the treatment group.
Study NCT00855192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindful meditation
Description: interpersonal and psycho-educational
Study NCT00855192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interpersonal therapy
Description: psycho-educational
Study NCT01093261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo:~continuous intra venous infusion of placebo n°1 for 10 days. enteral administration of placebo n°2 for 10 days.
Study NCT01093261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Fludrocortisone
Description: HYDROCORTISONE: 200 mg.day-1 for 7 days, 100 mg.day-1 on day 8 and 9, 50 mg on day-10 (continuous intravenous infusion) FLUDROCORTISONE: 50 microg.day-1 for 10 days (per os)
Study NCT01036087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 2.5 mg/kg IV on Day 1 of Week 1 over 60 minutes, followed by 2.5 mg/kg weekly Weeks 2-12.
Study NCT01036087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 100 mg/m2 IV over 30 min on Day 1 of Weeks 2-13 over 30 minutes.
Study NCT01036087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 2 IV over 30 min on Day 1 of Weeks 2-13 after completion of Abraxane through separate IV line.
Study NCT01036087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 500 mg/m2 IV every 3 weeks, starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
Study NCT01036087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 100 mg/m2 IV over 30 min every 3 weeks starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
Study NCT01036087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m2 IV every 3 weeks starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
Study NCT02089451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Drug: insulin aspart (faster acting insulin aspart) Subjects will receive five single dose level of faster acting insulin aspart. Three single dose s.c under the skin (abdomen, deltoid/upper arm, thigh), one single dose i.m. (intramuscularly, into the muscle) and one single dose i.v. (intravenously, into the vein)
Study NCT04364945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: administration of dexmedetomidine 1 mcg/kg/hr
Study NCT04364945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: administration of remifentanil 0.1-0.2 mcg/kg/min
Study NCT04364945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane
Description: Anesthesia is maintained using sevoflurane.
Study NCT04364945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Anesthesia is maintained using sevoflurane.
Study NCT02708641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg IV given every three weeks
Study NCT04376983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation for patients with a cardiac resynchronisation device
Description: Using the device-measured physical activity to create tailored motivational messages and tips to the patients to increase physical activity
Study NCT02580682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sanfu herbal patch
Description: The formula of the patch consists of Huang Qi (Astagalus Membranaceus), Fu Zi (Aconiti Lateralis Radix Praeparata), Yan Hu Suo (Rhizoma Corydalis), Xi Xin (Herba As5ari), Bai Jie Zi (Semen Sinapis Albae) and Rou Gui(Cortex Cinnamomi), in a proportion of 2:2:1:1:2:1.
Study NCT02580682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sanfu moxibustion
Description: Moxibustion is a kind of thermal therapy without any feeling of pain or swell.Moxibustion exerts its therapeutic effect by thermal power and the application of moxa.
Study NCT02580682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sanfu herbal patch and moxibustion
Description: use Sanfu moxibustion followed by Sanfu herbal patch
Study NCT03826563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral melatonin tablets (NatureMade brand)
Description: melatonin tablets
Study NCT03826563 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: pill placebo
Study NCT01530399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDCO 1
Description: MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 1: load 15 μg/kg; infusion 30 μg/kg/h; CPB prime 0.11 μg/mL priming volume
Study NCT01530399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDCO 2
Description: MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 2: load 30 μg/kg; infusion 60 μg/kg/h; CPB prime 0.22 μg/mL priming volume
Study NCT03098927 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor imagery training
Description: Motor imagery training
Study NCT01530399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDCO 3
Description: MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 3: load 60 μg/kg ; infusion 120 μg/kg/h; CPB prime 0.44 μg/mL priming volume
Study NCT01530399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDCO 4
Description: MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 4: load 90 μg/kg; infusion 180 μg/kg/h; CPB prime 0.65 μg/mL priming volume
Study NCT01530399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic acid will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with tranexamic acid. The flow rates will be the same as for MDCO-2010.
Study NCT01530399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: A loading dose of saline will be followed by a continuous infusion of saline until sternal closure. In addition, the CPB reservoir will be primed with saline. The flow rates will be the same as for MDCO-2010.